2 - TI Pharma

Chapter 2 Glucocorticoids: metabolic side effects
46. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in
healthy humans. Am j Physiol. 1998;275(5 Pt 1):E806-13.
47. Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on
fuel metabolism and insulin binding to monocytes in normal humans. j Clin Endocrinol Metab.
1980;50(3):495-501.
48. Wajngot A, Khan A, Giacca A, Vranic M, Efendic S. Dexamethasone increases glucose cycling, but not
glucose production, in healthy subjects. Am j Physiol. 1990;259(5 Pt 1):E626-32.
49. jin jY, Dubois DC, Almon RR, jusko Wj. Receptor/gene-mediated pharmacodynamic effects of
methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. j Pharmacol Exp
Ther. 2004;309(1):328-39.
50. Sasaki K, Cripe TP, Koch SR, Andreone TL, Petersen DD, Beale EG et al. Multihormonal regulation of
phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. j Biol Chem.
1984;259(24):15242-51.
51. Vander Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, Vander Kooi CW, Chazin WJ, O’Brien RM.
The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative
glucocorticoid response elements. Mol Endocrinol. 2005;19(12):3001-22.
52. Zimmerman T, Horber F, Rodriguez N, Schwenk WF, Haymond MW. Contribution of insulin resistance
44
to catabolic effect of prednisone on leucine metabolism in humans. Diabetes. 1989;38(10):1238-44.
53. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev. 1984;64(1):170-
259.
54. Whorwood CB, Donovan Sj, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor
expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic
syndrome. Diabetes. 2002;51(4):1066-75.
55. Chevalier S, Burgess SC, Malloy CR, Gougeon R, Marliss EB, Morais jA. The greater contribution
of gluconeogenesis to glucose production in obesity is related to increased whole-body protein
catabolism. Diabetes. 2006;55(3):675-81.
56. Dirlewanger M, Schneiter PH, Paquot N, jequier E, Rey V, Tappy L. Effects of glucocorticoids on
hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19(1):29-34.
57. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP,
Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent
in LDL receptor-null mice. Nat Med 2003;9(8):1069-75.
58. Bernal-Mizrachi C, Xiaozhong L, Yin L, Knutsen RH, Howard Mj, Arends jj, Desantis P, Colemant
T, Semenkovich CF. An afferent vagal nerve pathway links hepatic PPARalpha activation to
glucocorticoid-induced insulin resistance and hypertension. Cell Metab. 2007;5(2):91-102.
59. Van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)alpha:
a pharmacological target with a promising future. Pharm Res. 2004;21(9):1531-8.